N-Zyme Biomedical Raises $4.6 Million Series A To Advance Reflux Disease Treatments: N-Zyme Biomedical has raised approximately $4.6 million in Series A funding to advance Phase 2 clinical programs evaluating its pepsin inhibitor platform for reflux disease. The financing is expected to fully fund the company’s planned Phase 2 work in laryngopharyngeal reflux and proton pump inhibitor-refractory gastroesophageal reflux disease. The post N-Zyme Biomedical Raises $4.6 Million Series A To Advance Reflux Disease Treatments appeared first on Pulse 2.0.